New data from a post-hoc analysis of the phase 3a SCALE™ clinical trial program were presented at the European Congress on Obesity (ECO), demonstrated that Novo Nordisk’s Saxenda (liraglutide 3 mg) has benefits beyond weight loss.

 “…The post-hoc analysis confirmed that weight loss has a positive impact on a number of cardiometabolic risk factors, including high blood pressure and cholesterol. However, we also saw the direct effect of liraglutide 3 mg on glycemic control and other endpoints, independent of weight loss,” said Professor Luc Van Gaal, head of the Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, and SCALE™ trial investigator.

Endpoints that improved due to liraglutide 3 mg treatment, but were independent of weight loss (18-32 percent) included glycemic endpoints (HbA1c and fasting plasma glucose), as well as a reduction in use of oral anti-diabetic treatments. However, reduction in bodyweight still contributed to these treatment effects, according to Novo Nordisk.

 Source: Novo Nordisk